Drugs / STMC-103H
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03819881 | Oct 2018 → Nov 2019 | atopic IgE-mediated allergic disorder | Siolta Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05003804 | Sep 2021 → Nov 2024 | atopic eczema | Siolta Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STMC-103H | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05003804 ↗ |
| Modality | Other / unclassified | “This is a first-in-human trial of this live biotherapeutic product.” NCT03819881 ↗ |
| Route | Oral | “Oral administration of STMC-103H twice daily” NCT03819881 ↗ |